Dr Carlo Incerti oversees Global Medical Affairs in the four Therapeutic Areas of Sanofi Genzyme, a Global Business Unit of Sanofi Corporation: oncology, immunology, multiple sclerosis and rare diseases. Dr Incerti is a Board Certified Endocrinologist who started his career in the medical profession as a staff member and then as Associate Professor at the Department of Endocrinology of Modena University Hospital in Italy.
He joined Genzyme in 1992 and in his tenure, which covers more than two decades, he has been responsible for the development of all of the Genzyme products, including those in the rare disease field, with specific focus on lysosomal storage disorders. These development activities started with the successful approval in Europe of what is considered the first pre-orphan drug (Cerezyme for Gaucher disease) and in the first officially approved orphan drug (Fabrazyme for Fabry disease).
He is currently Chairman of the EuropaBio Board, a member of the Board of EFPIA (European Federation of Pharmaceutical Industries and Associations), a member of the Board of MolMed Spa, and member of the Governing Board of IMI (the Innovative Medicines Initiative).
Dr Incerti is a founding member and part of the Consortium Assembly of IRDiRC (International Rare Disease Research Consortium), an international group which aims to foster the research and development of therapeutics for rare diseases.